DeDora Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

DeDora Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-81	Closed	-$6K	–	139
2022 Q1	$6K	Buy	+81	New	+$6.78K	﹤0.01%	334

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DeDora Capital's BMRN Position: Q2 2022 in Review

DeDora Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 81 shares — an estimated $6K sold.

DeDora Capital first reported a position in BMRN in Q1 2022 and held it in 1 quarter. The position peaked at $6K in Q1 2022. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

DeDora Capital reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
DeDora Capital sold 81 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $6K.
DeDora Capital first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 1 quarter.
DeDora Capital's BioMarin Pharmaceuticals position peaked at $6K in Q1 2022.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on DeDora Capital's 13F filing for Q2 2022, filed 27 Jul 2022.